EXPERIMENTAL PROTOCOL FOR DEVELOPING AN ASSOCIATION BETWEEN PHENOBARBITAL AND MEDICINAL CANNABINOID FOR THE TREATMENT OF INDUCED EPILEPSY IN WISTAR RATS.
CBD, Cannabis sp, seizures, Phenobarbital. Temporal lobe epilepsy
Epilepsy is a neurogenic disorder in which brain functions can be affected and there is an alteration in neuronal communication with depolarizations and hyperpolarizations in regions of the central nervous system. Some diseases can present chronic epileptiform seizures with several associated symptoms and are difficult to treat. The first-line drug to be used in allopathic therapy is phenobarbital, a low-cost drug that has demonstrated its efficiency with good results in relation to the number of people who respond to its use (about 80%) and in the reduction of the number of seizures. The pharmacokinetics of this drug is metabolized almost entirely by the liver and has renal excretion of about ¼ of the applied dose. However, continuous use in treatment demonstrated the action of Cannabidiol transdermally in responses to the labyrinths analyzed, as well as in the control of neuronal mortality. Another important tool was the response of transdermal CBD associated with phenobarbital in therapeutic dosage on histopathological changes and on the activity of central nervous system cells. Thus, this pathway and association may be a path for future treatments and therapeutic associations.